These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28803840)

  • 21. Development and Validation of the American Heart Association's PREVENT Equations.
    Khan SS; Matsushita K; Sang Y; Ballew SH; Grams ME; Surapaneni A; Blaha MJ; Carson AP; Chang AR; Ciemins E; Go AS; Gutierrez OM; Hwang SJ; Jassal SK; Kovesdy CP; Lloyd-Jones DM; Shlipak MG; Palaniappan LP; Sperling L; Virani SS; Tuttle K; Neeland IJ; Chow SL; Rangaswami J; Pencina MJ; Ndumele CE; Coresh J;
    Circulation; 2024 Feb; 149(6):430-449. PubMed ID: 37947085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study.
    Hippisley-Cox J; Coupland C
    BMJ; 2015 Nov; 351():h5441. PubMed ID: 26560308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
    BMJ; 2011 Nov; 343():d6898. PubMed ID: 22115901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data.
    Ahmad Kiadaliri A; Gerdtham UG; Nilsson P; Eliasson B; Gudbjörnsdottir S; Carlsson KS
    PLoS One; 2013; 8(5):e62650. PubMed ID: 23671618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study.
    Hippisley-Cox J; Coupland C
    BMJ; 2017 Nov; 359():j5019. PubMed ID: 29158232
    [No Abstract]   [Full Text] [Related]  

  • 26. Microvascular Disease and Incident Heart Failure Among Individuals With Type 2 Diabetes Mellitus.
    Kaze AD; Santhanam P; Erqou S; Ahima RS; Bertoni A; Echouffo-Tcheugui JB
    J Am Heart Assoc; 2021 Jun; 10(12):e018998. PubMed ID: 34107742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. External validation and calibration of risk equations for prediction of diabetic kidney diseases among patients with type 2 diabetes in Taiwan.
    Su HY; Nguyen TTD; Lin WH; Ou HT; Kuo S
    Cardiovasc Diabetol; 2024 Oct; 23(1):357. PubMed ID: 39385193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial.
    Baum A; Scarpa J; Bruzelius E; Tamler R; Basu S; Faghmous J
    Lancet Diabetes Endocrinol; 2017 Oct; 5(10):808-815. PubMed ID: 28711469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the Basque Country Prospective Complications and Mortality Study risk engine (BASCORE).
    Piniés JA; González-Carril F; Arteagoitia JM; Irigoien I; Altzibar JM; Rodriguez-Murua JL; Echevarriarteun L;
    Diabetologia; 2014 Nov; 57(11):2324-33. PubMed ID: 25212259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
    Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
    Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register.
    Read SH; van Diepen M; Colhoun HM; Halbesma N; Lindsay RS; McKnight JA; McAllister DA; Pearson ER; Petrie JR; Philip S; Sattar N; Woodward M; Wild SH;
    Diabetes Care; 2018 Sep; 41(9):2010-2018. PubMed ID: 30002197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BMI and BMI change following incident type 2 diabetes and risk of microvascular and macrovascular complications: the EPIC-Potsdam study.
    Polemiti E; Baudry J; Kuxhaus O; Jäger S; Bergmann MM; Weikert C; Schulze MB
    Diabetologia; 2021 Apr; 64(4):814-825. PubMed ID: 33452586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes.
    Kengne AP; Patel A; Marre M; Travert F; Lievre M; Zoungas S; Chalmers J; Colagiuri S; Grobbee DE; Hamet P; Heller S; Neal B; Woodward M;
    Eur J Cardiovasc Prev Rehabil; 2011 Jun; 18(3):393-8. PubMed ID: 21450612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severity of Cardiovascular Autonomic Neuropathy Is a Predictor Associated With Major Adverse Cardiovascular Events in Adults With Type 2 Diabetes Mellitus: A 6-Year Follow-up Study.
    Lai YR; Huang CC; Chang HW; Chiu WC; Tsai NW; Cheng BC; Chen JF; Lu CH
    Can J Diabetes; 2021 Mar; 45(2):155-161. PubMed ID: 33046397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study.
    Davis WA; Colagiuri S; Davis TM
    Med J Aust; 2009 Feb; 190(4):180-4. PubMed ID: 19220181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electronic Medical Record Risk Modeling of Cardiovascular Outcomes Among Patients with Type 2 Diabetes.
    Hong D; Fort D; Shi L; Price-Haywood EG
    Diabetes Ther; 2021 Jul; 12(7):2007-2017. PubMed ID: 34143415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis.
    Vetrone LM; Zaccardi F; Webb DR; Seidu S; Gholap NN; Pitocco D; Davies MJ; Khunti K
    Acta Diabetol; 2019 Mar; 56(3):331-339. PubMed ID: 30456728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
    Charytan DM; Solomon SD; Ivanovich P; Remuzzi G; Cooper ME; McGill JB; Parving HH; Parfrey P; Singh AK; Burdmann EA; Levey AS; Eckardt KU; McMurray JJV; Weinrauch LA; Liu J; Claggett B; Lewis EF; Pfeffer MA
    Diabetes Obes Metab; 2019 May; 21(5):1199-1208. PubMed ID: 30672083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiorespiratory Fitness and Atherosclerotic Cardiovascular Outcomes by Levels of Baseline-Predicted Cardiovascular Risk: The Look AHEAD Study.
    Kaze AD; Santhanam P; Erqou S; Bertoni AG; Ahima RS; Echouffo-Tcheugui JB
    Am J Med; 2021 Jun; 134(6):769-776.e1. PubMed ID: 33607087
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.